Regulatory 2023-06-16 | Ascelia Pharma presented Orviglance Hepatic Impairment Data and hosted a Q&A with liver imaging experts at the 2023 ESGAR Annual Meeting PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2023-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2023 PDF Report Presentation Webcast
2023-04-25 | Hepatic Impairment Study Accepted for Presentation at Major Radiology and Liver Conferences PDF Report Presentation Webcast
Regulatory 2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-13 | Ascelia Pharma publishes annual report for 2022 PDF Report Presentation Webcast
Regulatory 2023-04-03 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
2023-03-14 | Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Market – Next Steps Towards Launch PDF PDF Report Presentation Webcast
Regulatory 2023-03-13 | Ascelia Pharma Mourns the Passing of Board Member René Spogárd PDF Report Presentation Webcast
2023-03-13 | Third US patent strengthens patent protection for Ascelia Pharma’s Oncoral (daily tablet irinotecan) PDF Report Presentation Webcast
2023-03-06 | INVITATION TO ASCELIA PHARMA INVESTOR UPDATE: BRINGING ORVIGLANCE TO MARKET – NEXT STEPS TOWARDS LAUNCH PDF Report Presentation Webcast
2023-03-03 | Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients. PDF Report Presentation Webcast
Regulatory 2023-02-28 | Change in number of shares and votes in Ascelia Pharma AB PDF Report Presentation Webcast
2023-02-24 | Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE PDF Report Presentation Webcast
Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
